191 results on '"Hatanaka, Kazuteru"'
Search Results
2. Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
3. Very urgent endoscopic retrograde cholangiopancreatography is associated with early
4. Successful closure of a detached muscle layer during gastric endoscopic submucosal dissection with fibrosis using clips with the use of polyglycolic acid sheets and fibrin glue
5. Successful ESD of a gastric hamartomatous inverted polyp intussuscepted into a pylorus ring using a clip with a line attachment prior to incision
6. Successful Creation of the Mucosal Flap in the Colorectal Endoscopic Submucosal Dissection Using a Push-Up, Grasp, and Cutting Technique
7. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
8. HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
9. Successful direct clipping of the bleeding source of a colonic diverticular hemorrhage using the “long-hood gel-filling” method
10. Effects of activation of an alcohol metabolic gene, cigarette smoking, and alcohol intake on the incidence of metachronous gastric cancer in patients who underwent endoscopic resection for gastric cancer: A multicenter retrospective pilot study
11. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
12. Detailed Observation of Fish Tapeworm Using Colonoscopy
13. Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
14. Red dichromatic imaging improved the visibility of exposed blood vessels in gastric ulcer induced by endoscopic submucosal dissection– a pilot study
15. Successful Resection of a Gastric Tumor With Severe Fibrosis Using Endoscopic Submucosal Tunnel Dissection and a Picking Technique With a Clutch Cutter
16. O15-2 HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy
17. FEASIBILITY OF A NEW LIGATION USING THE DOUBLE-LOOP CLIPS TECHNIQUE WITHOUT AN ADHESIVE AGENT FOR ULCERATION AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION OF THE COLON
18. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
19. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
20. HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer.
21. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
22. Long-term outcomes and risk factors of recurrent biliary obstruction after permanent endoscopic biliary stenting for choledocholithiasis in high-risk patients
23. O3-9-3 - Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
24. O2-8-2 - Phase II trial of Panitumumab for patients with KRAS exon2 wild type mCRC after progression on Cetuximab: HGCSG1101
25. HGCSG1902 Multicenter, Prospective, Observational Study of Chemotherapy-induced Dysgeusia in Gastrointestinal Cancer
26. Successful resection of protruding tumor with muscle-retracting sign during rectal endoscopic submucosal dissection using isolation method and picking technique with clutch cutter
27. P29-1 The results of the questionnaire survey of oral steroids for patients with cancer-related fatigue
28. Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
29. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan
30. Very urgent endoscopic retrograde cholangiopancreatography is associated with early discharge in patients with non-severe acute cholangitis
31. Red dichromatic imaging helps in detecting exposed blood vessels in gastric ulcer induced by endoscopic submucosal dissection
32. A new endoscopic fixation method using the commercially available Multi-Clamp: the “clamp technique”
33. Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study
34. HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
35. Clip with thread attachment prior to incision – new strategy for traction-assisted esophageal endoscopic submucosal dissection
36. HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy—Updated analysis of antitumor efficacy.
37. A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade.
38. The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.
39. Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603)
40. The impact of UGT1A1 single-hetero regarding the toxicity of fixed dose irinotecan therapy for advanced gastric cancer
41. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab
42. Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.
43. Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.
44. HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer
45. Comparison of administration status and adverse events in each cancer type using ramucirumab
46. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.
47. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
48. Phase II trial of Panitumumab for patients with KRAS exon2 wild type mCRC after progression on Cetuximab: HGCSG1101
49. Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
50. MO2-2-1 - The impact of UGT1A1 single-hetero regarding the toxicity of fixed dose irinotecan therapy for advanced gastric cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.